Myositis clinical trials

Explore recruiting myositis clinical trials.

Recruiting myositis studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Myositis trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Intravenous immunoglobulin and prednisone vs. prednisone in newly diagnosed myositis: a double blind randomized clinical trial

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart in Adults With Dermatomyositis

Greece, Poland, Italy, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

Drug Rediscovery for rare Immune Mediated Inflammatory Diseases (DRIMID)

Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II/III Randomized, Double-blind, Placebo-controlled, Multicenter Study to Determine the Efficacy and Safety of ABC008 in the Treatment of Subjects with Inclusion Body Myositis

Belgium, Germany, France

Phase II and Phase III (Integrated) EU CTIS Study details

Cell therapy for Inclusion Body Myositis (IBM) by muscle injection of autologous uncultured Adipose-Derived Stromal Vascular Fraction (ADSVF): a phase I trial

France

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

MYOCIT - Baricitinib in the treatment of new-onset juvenile dermatomyositis: a phase II trial

France

Therapeutic exploratory (Phase II) EU CTIS Study details

Myositis trials by city

Myositis in Toronto Myositis in Vancouver Myositis in Montreal Myositis in Calgary Myositis in Edmonton Myositis in Ottawa Myositis in Winnipeg Myositis in Quebec City Myositis in Hamilton Myositis in Kitchener Myositis in London Myositis in Halifax Myositis in New York Myositis in Los Angeles Myositis in Chicago Myositis in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease